Median 5 Year Follow-up of 125Iodine Brachytherapy as Monotherapy in Men Aged ≤ 55 Years With Favorable Prostate Cancer

Urology

Volumn 75, Issue 6, 2010, Pages 1412-1416

  Gómez Iturriaga Piña, Alfonso ^a   Crook, Juanita ^a   Borg, Jette ^a   Lockwood, Gina ^a   Fleshner, Neil ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; IODINE 125; MESALAZINE; PHENAZOPYRIDINE; PHOSPHODIESTERASE V INHIBITOR; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BRACHYTHERAPY; CANCER RECURRENCE; DYSURIA; ERECTILE DYSFUNCTION; FOLLOW UP; GLEASON SCORE; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROCTITIS; PROSTATE CANCER; SIDE EFFECT; TRANSURETHRAL RESECTION; URETHRA STRICTURE; URETHRITIS; URINARY FREQUENCY; URINARY URGENCY; URINE RETENTION;

AGE FACTORS; BIOPSY, NEEDLE; BRACHYTHERAPY; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ERECTILE DYSFUNCTION; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; IODINE RADIOISOTOPES; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROBABILITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RELATIVE BIOLOGICAL EFFECTIVENESS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; URINARY INCONTINENCE;

EID: 77952744809     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.04.101     Document Type: Article

References (29)

1. Smith C.V., Bauer J.J., Connelly R.R., et al. Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database. J Urol 164 (2000) 1964-1967
2. Khan M.A., Han M., Partin A.W., et al. Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology 62 (2003) 86-91 discussion 91-92
3. Merrick G.S., Butler W.M., Wallner K.E., et al. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer. Urology 64 (2004) 754-759
4. Zelefsky M.J., Marion C., Fuks Z., et al. Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy. J Urol 170 (2003) 1828-1832
5. Huguenin P.U., Bitterli M., Lutolf U.M., et al. Localized prostate cancer in elderly patients. Outcome after radiation therapy compared to matched younger patients. Strahlenther Onkol 175 (1999) 554-558
6. Peschel R.E., Khan A., Colberg J., et al. The effect of age on prostate implantation results. Cancer J 12 (2006) 305-308
7. Merrick G.S., Wallner K.E., Butler W.M., et al. Brachytherapy in men aged < or = 54 years with clinically localized prostate cancer. BJU Int 98 (2006) 324-328
8. Crook J., Gillan C., Yeung I., et al. PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. Int J Radiat Oncol Biol Phys 69 (2007) 426-433
9. Trotti A., Colevas A.D., Setser A., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13 (2003) 176-181
10. Catalona W.J., Smith D.S., Ratliff T.L., et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270 (1993) 948-954
11. Catalona W.J., Smith D.S., Ratliff T.L., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324 (1991) 1156-1161
12. Cooner W.H., Mosley B.R., Rutherford Jr. C.L., et al. Clinical application of transrectal ultrasonography and prostate specific antigen in the search for prostate cancer. J Urol 139 (1988) 758-761
13. Freedman G.M., Hanlon A.L., Lee W.R., et al. Young patients with prostate cancer have an outcome justifying their treatment with external beam radiation. Int J Radiat Oncol Biol Phys 35 (1996) 243-250
14. Ruska K.M., Partin A.W., Epstein J.I., et al. Adenocarcinoma of the prostate in men younger than 40 years of age: diagnosis and treatment with emphasis on radical prostatectomy findings. Urology 53 (1999) 1179-1183
15. Kollmeier M.A., Stock R.G., and Stone N. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 57 (2003) 645-653
16. Critz F.A., and Levinson K. 10-year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology. J Urol 172 (2004) 2232-2238
17. Sylvester J.E., Grimm P.D., Blasko J.C., et al. 15-Year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys 67 (2007) 57-64
18. Potters L., Morgenstern C., Calugaru E., et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 173 (2005) 1562-1566
19. Grimm P.D., Blasko J.C., Sylvester J.E., et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 51 (2001) 31-40
20. Jani A.B., and Hellman S. Early prostate cancer: hedonic prices model of provider-patient interactions and decisions. Int J Radiat Oncol Biol Phys 70 (2008) 1158-1168
21. Merrick G.S., Butler W.M., Wallner K.E., et al. Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys 62 (2005) 437-447
22. Schiff J.D., Bar-Chama N., Cesaretti J., et al. Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function. BJU Int 98 (2006) 1255-1258
23. Gillan C., Kirilova A., Landon A., et al. Radiation dose to the internal pudendal arteries from permanent-seed prostate brachytherapy as determined by time-of-flight MR angiography. Int J Radiat Oncol Biol Phys 65 (2006) 688-693
24. McLaughlin P.W., Narayana V., Meirovitz A., et al. Vessel-sparing prostate radiotherapy: dose limitation to critical erectile vascular structures (internal pudendal artery and corpus cavernosum) defined by MRI. Int J Radiat Oncol Biol Phys 61 (2005) 20-31
25. Merrick G.S., Butler W.M., Lief J.H., et al. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys 47 (2000) 121-128
26. Herstein A., Wallner K., Merrick G., et al. I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial. Cancer J 11 (2005) 385-389
27. Andersson S.O., Rashidkhani B., Karlberg L., et al. Prevalence of lower urinary tract symptoms in men aged 45-79 years: a population-based study of 40 000 Swedish men. BJU Int 94 (2004) 327-331
28. Liauw S.L., Sylvester J.E., Morris C.G., et al. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up. Int J Radiat Oncol Biol Phys 66 (2006) 669-673
29. Gutman S.A., Merrick G.S., Butler W.M., et al. Temporal relationship between prostate brachytherapy and the diagnosis of colorectal cancer. Int J Radiat Oncol Biol Phys 66 (2006) 48-55